Gene Therapies Casgevy and Lyfgenia Infusions Begin for Sickle Cell Patients
Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy Casgevy has started infusing patients with edited cells, following the company’s second-quarter earnings report on August 1. This marks a breakthrough in sickle cell treatment, as experts predicted a slow uptake due to the complex process of undergoing treatment, which can take up to a year. Meanwhile, bluebird … Read more